Prostate-specific membrane antigen (PSMA) is a transmembrane protein with overexpression in most prostate cancer cells. Gallium-68-( 68 Ga) PSMA positron emission tomography/computed tomography (PET/CT) imaging is a game-changer in the management of prostate cancer. 68 Ga PSMA PET/CT scan is advanced and a promising radioligand has high sensitivity in determining lesions of prostate cancer with a high tumor to background ratio. The most common areas of metastasis are the bone and pelvic lymph nodes. The prognosis of prostate cancer is mainly determined by the status of metastases. The presence and the localization of metastases affects treatment planning. In our cases, we presented some examples of uncommon sites of metastases such as the brain, adrenal glands, penis and orbit. Improvements in imaging techniques, such as 68 Ga PSMA PET/CT have led to the possibility to make more determi nation of rare metastase sites in prostate cancer patients.
The study aims to evaluate the radiation safety conditions by detecting the patient’s urine excretion rate, calculating the effective half-life, and determining the retention of 177Lu-PSMA in the body. Urine samples of patients were collected for 24 hours (6, 12, 18, and 24 hours) following the infusion, excretion rate and retention of 177Lu-PSMA in the body of patients were calculated. The measurements of dose rate were performed. Effective half-life calculated from dose rate measurements was found as 18.5 ± 11 h within the first 24 h and 48.1 ± 22.8 h between 24 and 72 h. Excreted activity in urine was found as 33.8 ± 20.7, 40.4 ± 20.3, 46.1 ± 22.4, and 53.3 ± 21.5% of total doses at 6, 12, 18, and 24 h after administration, respectively. External dose rates for 4 h and 24 h were 24.51 μSv/h, 16.14 μSv/h, respectively. Our results showed that 177Lu-PSMA treatment was suitable for outpatient treatment in terms of radiation safety.
Bladder hernias usually begin asymptomatically and are discovered incidentally at the time of discovery. Preoperative diagnosis of bladder hernias is important to reduce the risk of bladder injury during surgery. Although F-18 FDG PET/CT is applied for oncological purposes, benign conditions should also be taken into account when evaluating the implants. In this article, a case of bladder hernia, which can be confused with pathological cancer involvement, with the diagnosis of F-18 FDG PET/CT performed in a 73-year-old male patient with renal cell carcinoma is presented.
Introductıon F-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) is increasingly used in tumor diagnosis, staging, treatment response evaluation, and radiotherapy planning. Combined PET/CT devices provide both metabolic information from F-18 FDG PET and anatomical information from CT in a single imaging (1). The most important difference of PET/CT from radiological imaging methods such as direct radiographs and CT, which provides structural information about various diseases, is that it provides functional information. In functional imaging, it is possible to monitor tissue perfusion, glucose metabolism and receptor activities by using appropriate methods and imaging agents (2). Giriş: Çalışmanın amacı, florodeoksiglukoz-pozitron emisyon tomografi/bilgisayarlı tomografi görüntüleme (FDG-PET/BT) yapılan hastaların karaciğer ve kan havuzundaki bazal SUV maks aralığının tanımlanmasıdır. Yöntemler: Bölümümüze tedavi öncesi PET/BT görüntüleme için gelen 531 hasta (264 kadın, 267 erkek; yaş ortalaması 59,6±13,4 yıl) çalışmaya dahil edildi. Tüm hastalar için PET/BT görüntüleme öncesi hasta hazırlığı, aküzisyon parametreleri ve rekonstrüksiyon protokolleri standardize edildi. Hastaların ortalama serum glukoz seviyeleri ve yaş ortalamaları hesaplandı. Bu hastalar özofagus, mide, kolon, rektum, larinks, akciğer, meme, lenfoma, endometrium ve over kanserleri olmak üzere 10 gruba ayrıldı. Karaciğerin sağ lobuna ve kan havuzu için aort kavisine ortalama SUV değerlerinin hesaplanabilmesi için 2 boyutlu ilgi alanı bölgeleri çizildi. Bulgular: Hastaların gruplar arası karaciğer ve kan havuzu için ortalama SUV değişimlerinin normal Gaussian dağılımları elde edildi. Ortalama SUV maks ve SUV ort değerleri karaciğer için sırasıyla 2,73±0,22, 2,34±0,16; kan havuzu için 1,80±0,2, 1,57±0,14 olarak hesaplandı. Sonuç: Elde edilen SUV aralıklarının kanserli olgularda kalitatif tümör cevabı değerlendirmede ve tumör/background oranlarını kıyaslamada klinikte uygulama kolaylığı sağlayabileceği kanaatine varıldı. Anahtar Kelimeler: PET/BT, SUV ölçümü, tümör background oranı ÖZ Introduction: The aim of the study was to define the baseline SUV max range in the liver and blood pool of patients undergoing fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) imaging. Methods: Five hundred and thirty-one patients (264 females, 267 males; mean age: 59.6±13.4 years) who were admitted to our department for PET/CT imaging before treatment were included in the study. Patient preparation, acquisition parameters and reconstruction protocols were standardized for all patients prior to PET/CT imaging. The mean serum glucose levels and mean age of the patients were calculated. These patients were divided into 10 groups as esophagus, stomach, colon, rectum, larynx, lung, breast, endometrium, ovarian cancers and lymphoma. 2D region of interests were plotted to calculate the mean SUV values in the right lobe of the liver and the aortic arch for the blood pool. Results: Normal Gaussian distributi...
ABS TRACT Prostate-specific membrane antigen (PSMA) is a transmembrane protein with overexpression in most prostate cancer cells. Gallium-68-PSMA (68Ga-PSMA) positron emission tomography/computed tomography (PET/CT) imaging is a game changer within the management of prostate cancer. The prognosis of prostate cancer is principally determined by the metastatic condition. The presence and localization of metastasis have an effect on the selection of treatment protocol. We present the case of a prostate cancer patient with choroid metastasis demonstrated at 68Ga-PSMA PET/CT. In our case, we presented an example of an uncommon metastatic site such as choroid. Advances in imaging techniques such as 68Ga-PSMA PET/CT have led to more detection of rare metastatic sites in prostate cancer patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.